Evidence map›Paper›PMID 41994792›Full record

ArticleCureus2026

The Efficacy and Safety of N-acetylcysteine and Taurine (Nefrosave®) in Chronic Kidney Disease: A Double-Blind, Multicenter, Placebo-Controlled Trial (DELAY-CKD).

A K Bhalla, Sampath Kumar, Himanshu Verma, Geeta Sheth, Bismay Kumar, Rajib Mondal, Gayatri V Jayaraman, Nagashankar N, Monjori Mitra

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A K BhallaNephrology, Sir Ganga Ram Hospital, New Delhi, IND.
Sampath KumarNephrology, Meenakshi Mission Hospital, Madurai , IND.
Himanshu VermaNephrology, VMMC & Safdarjung Hospital, New Delhi, IND.
Geeta ShethNephrology, JJ Hospital, Mumbai, IND.
Bismay KumarNephrology, Kumar Hypertension and Kidney Clinic, Kolkata, IND.
Rajib MondalNephrology, BMRC Hospital, Kolkata, IND.
Gayatri V JayaramanInternal Medicine/Nephrology, Mass General Brigham Hospital System, Boston, USA.
Nagashankar NPharmacology, Fourrts India Laboratories, Chennai, IND.
Monjori MitraPediatrics, Institute of Child Health, Kolkata, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective Chronic kidney disease (CKD) is a progressive disorder with declining renal function and an elevated risk for end-stage renal disease (ESRD) and mortality. While oxidative stress is implicated in its pathogenesis, treatment using antioxidants remains uncertain. This study aimed to evaluate the effectiveness of the combination of N-acetylcysteine (NAC; 150 mg) and taurine (500 mg) in CKD. Methods A multicenter, double-blind, randomized, placebo-controlled trial was conducted across India between February 2021 and October 2023. Consenting adults aged 18-65 years with CKD stages 1-3 and serum creatinine <3.0 mg/dL were enrolled. Participants received NAC+taurine (Nefrosave

Indexed as

chronic kidney diseasecreatininecystatin cestimated glomerular filtration ratemicroalbuminurian-acetylcysteinetaurineurinary albumin-creatinine ratio

Identifiers

PMID41994792
PMCPMC13080957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.